Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ELDN stock here.
Eledon Pharmaceuticals (ELDN) completed enrollment of its phase 2 BESTOW trial using its immunosuppressive drug tegoprubart for the prevention of organ rejection in patients who undergo kidney ...
patient cohort fully enrolled with an average time since transplant of approximately 8 months- 100% insulin independence achieved in 10 ...
In patients with systemic lupus erythematosus (SLE) who had been in remission for at least 1 year, immunosuppressant withdrawal was noninferior to glucocorticoid withdrawal, with no significant ...
ROCKVILLE, Maryland, Dec. 29-- The American Kidney Fund issued the following statement: The following statement may be attributed to LaVarne A. Burton, president and CEO of the American Kidney Fund: ...
The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation ...
Briumvi (ublituximab-xiiy) is a prescription drug that’s used to treat relapsing multiple sclerosis. This drug can interact with other medications and vaccines. For example, Briumvi can interact with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results